Nilotinib Teva: Uses, Dosage & Side Effects
A second-generation BCR-ABL tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)
Nilotinib Teva is a prescription medication containing the active substance nilotinib, a potent second-generation tyrosine kinase inhibitor (TKI) used in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Nilotinib works by selectively blocking the BCR-ABL fusion protein, an abnormal enzyme that drives the uncontrolled growth of leukemic cells. It is indicated for both newly diagnosed adults with chronic phase CML and for adults with chronic or accelerated phase CML who are resistant to or intolerant of prior therapy, including imatinib. Nilotinib Teva is a generic equivalent of Tasigna, offering the same clinically proven efficacy and safety profile. The capsules must be taken on an empty stomach and require careful monitoring for cardiac and metabolic side effects.
Quick Facts: Nilotinib Teva
Key Takeaways
- Nilotinib Teva is a second-generation tyrosine kinase inhibitor used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in adults.
- The capsules must be taken on an empty stomach — no food for 2 hours before and 1 hour after each dose — to reduce the risk of cardiac side effects.
- QT prolongation is a serious potential side effect; regular ECG monitoring and electrolyte checks are essential throughout treatment.
- Nilotinib Teva is bioequivalent to the brand-name product Tasigna and has the same therapeutic effect, safety profile, and dosing requirements.
- Treatment-free remission may be possible for selected patients who achieve and maintain a deep molecular response under specialist supervision.
What Is Nilotinib Teva and What Is It Used For?
Nilotinib Teva contains the active substance nilotinib, which belongs to a class of medicines called tyrosine kinase inhibitors (TKIs). These medicines work by blocking specific proteins that are responsible for the abnormal growth of cancer cells. In chronic myeloid leukemia (CML), a genetic abnormality known as the Philadelphia chromosome produces an abnormal fusion protein called BCR-ABL, which acts as a constitutively active tyrosine kinase. This protein drives the uncontrolled proliferation of white blood cells that characterizes CML.
Nilotinib was specifically designed to bind to and inhibit the BCR-ABL protein with greater potency and selectivity than imatinib, the first-generation TKI that revolutionized CML treatment. In laboratory studies, nilotinib demonstrates approximately 20- to 30-fold greater potency against the wild-type BCR-ABL protein compared to imatinib. Importantly, nilotinib retains activity against most BCR-ABL mutations that confer resistance to imatinib, with the notable exception of the T315I mutation, which requires alternative treatment approaches.
Nilotinib Teva is a generic formulation manufactured by Teva Pharmaceutical Industries, one of the world's largest generic pharmaceutical companies. It has been demonstrated to be bioequivalent to the original brand-name product Tasigna (manufactured by Novartis), meaning it delivers the same amount of active drug to the body and produces the same clinical outcomes. Generic medications undergo rigorous regulatory review to ensure they meet the same standards of quality, safety, and efficacy as the originator product.
Approved Indications
Nilotinib Teva is approved by the European Medicines Agency (EMA) and other regulatory authorities worldwide for the following indications in adult patients:
- Newly diagnosed chronic phase CML: As first-line treatment for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Clinical trials have demonstrated superior rates of major molecular response (MMR) and deep molecular responses compared to imatinib in this setting.
- Resistant or intolerant chronic phase CML: For adults with chronic phase Ph+ CML who are resistant to or intolerant of prior therapy, including imatinib. Resistance may be due to BCR-ABL mutations, inadequate molecular response, or loss of previously achieved response.
- Resistant or intolerant accelerated phase CML: For adults with accelerated phase Ph+ CML who are resistant to or intolerant of prior therapy, including imatinib. The accelerated phase represents a more advanced stage of the disease with a higher burden of abnormal cells.
Nilotinib is not indicated for the treatment of blast crisis CML, as clinical evidence in this setting is limited. It is also not approved for use in pediatric patients under 18 years of age for the Nilotinib Teva formulation, although the originator product has pediatric approvals in some regions.
How Does Nilotinib Work?
The mechanism of action of nilotinib is highly targeted. The BCR-ABL fusion protein has a specific three-dimensional structure that includes an ATP-binding pocket. Under normal circumstances, the ABL kinase uses ATP (adenosine triphosphate) as an energy source to phosphorylate downstream signaling proteins, which in turn regulate cell growth, proliferation, and survival. In CML, the BCR-ABL fusion protein is locked in an active state, continuously sending proliferative signals regardless of the cell's actual needs.
Nilotinib binds to the inactive conformation of the ABL kinase domain with high affinity, competing with ATP for the binding site. By occupying this pocket, nilotinib effectively switches off the BCR-ABL signaling cascade. Without these growth signals, leukemic cells stop proliferating and undergo programmed cell death (apoptosis). The selectivity of nilotinib for BCR-ABL means that it has relatively limited effects on normal cells, though it also inhibits several other kinases including KIT, PDGFR (platelet-derived growth factor receptor), and DDR (discoidin domain receptor), which accounts for some of its side effects.
What Should You Know Before Taking Nilotinib Teva?
Contraindications
Nilotinib Teva must not be used in certain situations where the risks clearly outweigh any potential benefit. Before starting treatment, your doctor will carefully evaluate whether any of the following contraindications apply to you:
- Hypersensitivity: Do not take Nilotinib Teva if you are allergic to nilotinib or any of the other ingredients in the capsule. Allergic reactions may include rash, itching, swelling, or difficulty breathing.
- Hypokalemia or hypomagnesemia: Low blood levels of potassium or magnesium must be corrected before starting nilotinib, as these electrolyte imbalances significantly increase the risk of dangerous heart rhythm disturbances (QT prolongation and torsades de pointes).
- Long QT syndrome: Patients with congenital or acquired long QT syndrome should not take nilotinib due to the additive risk of cardiac arrhythmias.
Warnings and Precautions
Nilotinib prolongs the QT interval on the electrocardiogram (ECG). QT prolongation can lead to life-threatening cardiac arrhythmias, including torsades de pointes, ventricular tachycardia, and sudden cardiac death. Sudden deaths have been reported in patients taking nilotinib. Your doctor must perform an ECG before starting treatment, at 7 days after initiation, periodically thereafter, and after any dose adjustment. Electrolytes (potassium, magnesium, calcium) must be monitored and corrected before and during treatment.
Several additional precautions should be carefully considered before and during treatment with Nilotinib Teva:
- Cardiovascular events: Nilotinib has been associated with peripheral arterial occlusive disease (PAOD), ischemic heart disease, and ischemic cerebrovascular events. Patients with cardiovascular risk factors should be closely monitored. Cardiovascular risk assessment should be performed before starting treatment and regularly during therapy.
- Hepatotoxicity: Elevations of bilirubin, transaminases (ALT, AST), and alkaline phosphatase have been reported. Liver function tests should be performed monthly or as clinically indicated. Severe hepatotoxicity may require dose reduction or discontinuation.
- Pancreatitis: Cases of pancreatitis, including fatal cases, have been reported. Serum lipase levels should be checked periodically. If pancreatitis is suspected, nilotinib should be withheld and appropriate diagnostic workup initiated.
- Myelosuppression: Nilotinib can cause significant decreases in blood cell counts, including neutropenia, thrombocytopenia, and anemia. Complete blood counts should be performed every 2 weeks for the first 2 months of therapy and monthly thereafter.
- Fluid retention: Events such as pleural effusion, pericardial effusion, and edema have been reported. Patients should be monitored for signs and symptoms of fluid retention and treated as necessary.
- Tumor lysis syndrome: Patients with high tumor burden may be at risk for tumor lysis syndrome. Adequate hydration and correction of uric acid levels should be ensured before starting treatment.
- Lactose intolerance: Nilotinib Teva capsules contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
Pregnancy and Breastfeeding
Nilotinib Teva may cause harm to an unborn baby. Animal studies have shown reproductive toxicity, including embryo-fetal lethality and teratogenicity. Women of childbearing potential must use highly effective contraception during treatment and for at least 2 weeks after the last dose. Men taking nilotinib should also use effective contraception. If pregnancy occurs during treatment, the patient should be informed about the potential risks to the fetus. Breastfeeding is not recommended during treatment and for at least 2 weeks after the final dose, as nilotinib may pass into breast milk.
Women who are pregnant or think they may be pregnant should inform their doctor immediately before starting Nilotinib Teva. The decision to continue or discontinue nilotinib during pregnancy must be made on a case-by-case basis, weighing the potential risks to the fetus against the clinical need for treatment. CML management during pregnancy is a complex situation that requires involvement of both a hematologist and an obstetrician experienced in high-risk pregnancies.
Fertility may be affected by nilotinib. Both male and female patients should discuss fertility preservation options with their healthcare team before initiating treatment if future parenthood is desired.
How Does Nilotinib Teva Interact with Other Drugs?
Nilotinib has a complex interaction profile due to its metabolism by cytochrome P450 enzymes and its effects on several enzyme systems and drug transporters. Understanding these interactions is critical because even moderate changes in nilotinib blood levels can significantly affect both its efficacy and safety. The narrow therapeutic window of nilotinib means that plasma concentrations that are too low risk treatment failure, while levels that are too high increase the risk of serious toxicity, particularly QT prolongation.
Your healthcare provider should review all your current medications, including prescription drugs, over-the-counter medicines, herbal supplements, and dietary products before starting Nilotinib Teva. Some interactions can be managed with dose adjustments or increased monitoring, while others represent absolute contraindications to concurrent use.
Major Interactions
| Interacting Drug | Mechanism | Effect | Action |
|---|---|---|---|
| Ketoconazole, Itraconazole, Voriconazole | Strong CYP3A4 inhibition | Increased nilotinib levels (up to 3-fold) | Avoid concomitant use; use alternative antifungal |
| Clarithromycin, Telithromycin | Strong CYP3A4 inhibition | Increased nilotinib levels | Avoid; consider azithromycin as alternative |
| Rifampicin, Rifabutin | Strong CYP3A4 induction | Decreased nilotinib levels (up to 80%) | Avoid; risk of treatment failure |
| Phenytoin, Carbamazepine, Phenobarbital | Strong CYP3A4 induction | Significantly decreased nilotinib levels | Avoid; use alternative anticonvulsant |
| St. John's Wort (Hypericum) | CYP3A4 induction | Decreased nilotinib levels | Contraindicated during nilotinib treatment |
| QT-prolonging drugs (amiodarone, sotalol, haloperidol, methadone) | Additive QT prolongation | Increased risk of fatal arrhythmia | Avoid; if essential, intensive ECG monitoring |
Minor Interactions
Several other drug interactions require awareness and may necessitate dose adjustments or additional monitoring, though they do not necessarily require complete avoidance:
- Warfarin and other coumarin anticoagulants: Nilotinib inhibits CYP2C9, which metabolizes warfarin. Concurrent use may increase warfarin levels and the risk of bleeding. INR monitoring should be intensified if co-administration is necessary. Low-molecular-weight heparins are preferred alternatives.
- Midazolam and other CYP3A4 substrates: Nilotinib inhibits CYP3A4, potentially increasing levels of drugs metabolized by this enzyme. Use caution with narrow therapeutic index CYP3A4 substrates such as cyclosporine, tacrolimus, and certain statins.
- Proton pump inhibitors (PPIs) and H2-blockers: Nilotinib has pH-dependent solubility. Drugs that increase gastric pH may reduce nilotinib absorption. If antacid therapy is needed, separate dosing by at least 2 hours. H2-blockers should be taken approximately 10 hours before and 2 hours after nilotinib.
- Grapefruit and grapefruit juice: Grapefruit contains compounds that inhibit CYP3A4 in the gut wall, potentially increasing nilotinib absorption. Patients should avoid grapefruit products throughout treatment.
- Metformin and other P-glycoprotein substrates: Nilotinib inhibits P-glycoprotein (P-gp), an efflux transporter. This may increase levels of P-gp substrates such as digoxin and dabigatran. Monitor for increased toxicity of co-administered P-gp substrates.
Food significantly increases the absorption of nilotinib. Taking a 400 mg dose with a high-fat meal increases the area under the curve (AUC) by approximately 82% compared to fasting. This increase in bioavailability raises the peak plasma concentration and the risk of QT prolongation. Therefore, nilotinib must be taken on an empty stomach: no food should be consumed for at least 2 hours before and at least 1 hour after each dose. The capsules should be swallowed whole with water.
What Is the Correct Dosage of Nilotinib Teva?
The dosage of Nilotinib Teva is determined by your treating hematologist based on your specific clinical situation, including whether you are receiving first-line treatment or have previously been treated with other TKIs. Treatment should only be initiated by a physician experienced in the management of CML. The capsules should be swallowed whole with water approximately 12 hours apart, and strict fasting requirements must be observed.
Adults
Newly Diagnosed Chronic Phase CML
The recommended dose is 300 mg twice daily (total daily dose: 600 mg). Capsules are taken approximately 12 hours apart, for example at 8:00 AM and 8:00 PM. No food should be consumed for at least 2 hours before and at least 1 hour after each dose.
Resistant or Intolerant Chronic Phase and Accelerated Phase CML
The recommended dose is 400 mg twice daily (total daily dose: 800 mg). The same timing and fasting requirements apply. This higher dose reflects the need for greater BCR-ABL inhibition in patients with resistant disease or those who have already failed prior therapy.
| Indication | Dose | Frequency | Daily Total |
|---|---|---|---|
| Newly diagnosed CP-CML | 300 mg | Twice daily | 600 mg |
| Resistant/intolerant CP-CML | 400 mg | Twice daily | 800 mg |
| Resistant/intolerant AP-CML | 400 mg | Twice daily | 800 mg |
Children
Nilotinib Teva 50 mg hard capsules are not specifically indicated for use in children and adolescents under 18 years of age. While the originator product (Tasigna) has received approval for pediatric use in some regions, the dosing in children is weight-based and should only be determined by a pediatric hematologist/oncologist. The pediatric dose is generally calculated at approximately 230 mg/m² twice daily, rounded to the nearest 50 mg dose, with a maximum single dose of 400 mg. Parents and caregivers should consult their child's specialist team for specific dosing instructions.
Elderly
No specific dose adjustment is required for elderly patients based on age alone. However, older patients are more likely to have pre-existing cardiac conditions, reduced hepatic function, and electrolyte abnormalities that may increase the risk of side effects. Careful baseline assessment and ongoing monitoring are particularly important in this population. Cardiovascular risk factors should be evaluated and managed proactively, as the incidence of cardiovascular events with nilotinib appears to increase with age.
Hepatic Impairment
Nilotinib is extensively metabolized by the liver. Patients with mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C) should receive a reduced starting dose of 200 mg twice daily for newly diagnosed CML and 300 mg twice daily for resistant/intolerant CML, followed by potential dose escalation based on tolerability. Close monitoring of hepatic function is essential.
Missed Dose
If you miss a dose of Nilotinib Teva, do not take a double dose to make up for it. Simply take your next scheduled dose at the usual time. Maintaining a consistent dosing schedule is important for achieving and maintaining optimal drug levels, but it is safer to skip a single dose than to risk toxicity from doubling up. If you frequently forget doses, consider using a pill organizer or setting alarms to help establish a routine. Inform your doctor if you have missed multiple doses, as this may affect your treatment response.
Overdose
In case of overdose or accidental ingestion of more than the prescribed dose, contact your doctor, emergency department, or poison control center immediately. There is no specific antidote for nilotinib. Treatment is supportive, with particular attention to cardiac monitoring (continuous ECG) and correction of electrolyte abnormalities. Isolated cases of overdose have been reported at doses of up to 3,200 mg per day, with events including neutropenia, vomiting, and QT prolongation. Due to nilotinib's high protein binding, dialysis is unlikely to be effective.
What Are the Side Effects of Nilotinib Teva?
Like all medicines, Nilotinib Teva can cause side effects, although not everybody gets them. Some side effects may be serious and require immediate medical attention, while others are milder and often improve over time or with dose adjustments. The frequency and severity of side effects can vary depending on the dose (300 mg vs 400 mg twice daily), the duration of treatment, and individual patient factors.
Clinical trial data from the pivotal ENESTnd (newly diagnosed) and ENESTcmr studies, as well as post-marketing surveillance data, provide a comprehensive picture of the nilotinib safety profile. The side effect frequencies listed below are based on pooled data from clinical trials with more than 5,000 patients.
Very Common
Affects more than 1 in 10 patients
- Rash (various types including maculopapular, acneiform)
- Pruritus (itching)
- Headache
- Nausea
- Fatigue and asthenia
- Alopecia (hair thinning)
- Myalgia (muscle pain)
- Upper abdominal pain
- Thrombocytopenia (low platelets) — laboratory finding
- Neutropenia (low white blood cells) — laboratory finding
- Anemia (low red blood cells) — laboratory finding
- Elevated bilirubin (including hyperbilirubinemia)
- Elevated lipase
Common
Affects 1 in 10 to 1 in 100 patients
- Diarrhea or constipation
- Vomiting
- Abdominal pain or distension
- Dry skin, eczema, urticaria (hives)
- Arthralgia (joint pain), bone pain, musculoskeletal pain
- Peripheral edema (swelling of ankles/legs)
- Dizziness, insomnia
- QT prolongation on ECG
- Elevated transaminases (ALT, AST)
- Elevated blood glucose (hyperglycemia)
- Elevated cholesterol, triglycerides
- Decreased appetite
- Upper respiratory tract infection
- Night sweats, hyperhidrosis (excessive sweating)
- Weight gain or weight loss
Uncommon
Affects 1 in 100 to 1 in 1,000 patients
- Pancreatitis (inflammation of the pancreas)
- Pleural effusion (fluid around the lungs)
- Pericardial effusion (fluid around the heart)
- Peripheral arterial occlusive disease (PAOD)
- Ischemic heart disease (angina, myocardial infarction)
- Cerebrovascular events (stroke, TIA)
- Hepatotoxicity (significant liver injury)
- Gastrointestinal hemorrhage
- Erectile dysfunction
- Diabetes mellitus
- Tumor lysis syndrome
Rare
Affects fewer than 1 in 1,000 patients
- Sudden cardiac death
- Torsades de pointes (life-threatening arrhythmia)
- Anaphylactic reaction
- Hepatic failure
- Stevens-Johnson syndrome
- Erythema multiforme
- Hyperparathyroidism
Contact your doctor or seek emergency medical care immediately if you experience: severe chest pain or shortness of breath (may indicate cardiac arrhythmia or pericardial/pleural effusion), sudden severe abdominal pain radiating to the back (may indicate pancreatitis), yellowing of the skin or eyes (may indicate liver damage), sudden numbness or weakness on one side of the body (may indicate stroke), cold, pale, or blue extremities with pain (may indicate peripheral arterial occlusive disease), or signs of serious infection with high fever.
Long-term safety data from studies with follow-up periods exceeding 10 years have identified cardiovascular events, particularly peripheral arterial occlusive disease, as a key concern with prolonged nilotinib use. The risk appears to correlate with cumulative exposure and the presence of pre-existing cardiovascular risk factors such as diabetes, hypertension, hyperlipidemia, and smoking. Patients should have their cardiovascular risk profile assessed regularly and modifiable risk factors actively managed.
How Should You Store Nilotinib Teva?
Proper storage of Nilotinib Teva is essential to maintain the quality and effectiveness of the medication throughout its shelf life. The following guidelines should be followed carefully:
- Temperature: Store below 30°C (86°F). Do not refrigerate or freeze the capsules. Room temperature storage is suitable in most climate conditions.
- Moisture protection: Keep the capsules in the original blister packaging until you are ready to take them. The blister packaging provides protection from moisture, which can degrade the active ingredient.
- Light protection: Although not specifically required, it is good practice to store the capsules in a cool, dry place away from direct sunlight.
- Child safety: Keep this medicine out of the sight and reach of children. Nilotinib is a cytotoxic agent, and accidental ingestion by a child could have serious consequences.
- Expiry date: Do not use Nilotinib Teva after the expiry date (EXP) printed on the carton and blister. The expiry date refers to the last day of that month.
- Disposal: Do not dispose of medications via household waste or wastewater. Return any unused or expired capsules to your pharmacy for safe disposal. This helps protect the environment from cytotoxic contamination.
If you notice any visible changes in the appearance of the capsules, such as discoloration, unusual odor, or physical damage, do not take them. Contact your pharmacist for a replacement supply.
What Does Nilotinib Teva Contain?
Active Ingredient
The active substance in Nilotinib Teva is nilotinib, present as nilotinib hydrochloride monohydrate. Each hard capsule contains 50 mg of nilotinib. Nilotinib is a phenylamino-pyrimidine derivative that was rationally designed based on the crystal structure of the ABL kinase domain to achieve improved binding affinity and selectivity compared to imatinib. The chemical formula is C28H22F3N7O, and it has a molecular weight of 529.52 g/mol (free base).
Inactive Ingredients (Excipients)
The excipients in Nilotinib Teva capsules serve various pharmaceutical functions to ensure proper drug delivery, stability, and manufacturability:
- Lactose monohydrate: A filler/diluent that provides bulk to the capsule contents and aids in uniform distribution of the active ingredient.
- Crospovidone: A disintegrant that helps the capsule contents break apart and dissolve in the gastrointestinal tract.
- Poloxamer 188: A surfactant that improves the wettability and dissolution of the poorly soluble nilotinib.
- Colloidal silicon dioxide: A glidant that improves the flow properties of the powder blend during manufacturing.
- Magnesium stearate: A lubricant that prevents the powder from sticking to manufacturing equipment.
The capsule shell consists of gelatin, titanium dioxide (E171), and may contain iron oxide pigments for coloring. Patients with known hypersensitivity to any of these excipients should inform their healthcare provider.
Nilotinib Teva capsules contain lactose monohydrate as an excipient. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. The amount of lactose per capsule is generally small and is unlikely to cause symptoms in most patients with mild lactose intolerance, but this should be discussed with your pharmacist or doctor if you have concerns.
Frequently Asked Questions About Nilotinib Teva
Nilotinib Teva and Tasigna both contain the same active ingredient, nilotinib. Tasigna is the original brand-name product manufactured by Novartis, while Nilotinib Teva is a generic version manufactured by Teva Pharmaceutical Industries. They have been demonstrated to be bioequivalent through rigorous pharmacokinetic studies, meaning they deliver the same amount of active drug to the body and are expected to have the same therapeutic effect and safety profile. The primary difference is typically cost, with generic medications being more affordable. Both products must meet the same regulatory quality standards.
Taking nilotinib with food significantly increases its absorption — a high-fat meal can increase the drug's bioavailability by approximately 82%. This higher-than-intended blood level increases the risk of serious side effects, particularly QT prolongation, which can cause dangerous heart rhythm disturbances. To ensure safe and consistent drug levels, you must fast for at least 2 hours before and 1 hour after each dose. The capsules should be swallowed whole with water — do not open, crush, or chew them.
You must not stop taking Nilotinib Teva without consulting your doctor, even if you feel well. CML is a chronic condition that requires long-term treatment to keep it under control. Stopping treatment prematurely can lead to disease relapse. However, in carefully selected patients who have achieved and maintained a deep molecular response (MR4.5 or better) for at least 2 years, your specialist may discuss the possibility of treatment-free remission (TFR), a supervised discontinuation with very close molecular monitoring. Approximately 50% of patients who attempt TFR maintain their response without treatment, but this must only be done under specialist supervision.
Regular monitoring is essential during treatment with Nilotinib Teva. Your doctor will order: ECG (electrocardiogram) before starting treatment, at 7 days, and periodically thereafter to monitor the QT interval; complete blood counts every 2 weeks for the first 2 months, then monthly; liver function tests including bilirubin and transaminases; lipase levels to detect early signs of pancreatitis; electrolytes including potassium, magnesium, and calcium; fasting blood glucose and lipid profiles; and molecular monitoring via quantitative PCR for BCR-ABL transcript levels to assess treatment response. Cardiovascular risk assessment should also be performed regularly.
Nilotinib may affect fertility in both men and women. Animal studies have shown effects on reproductive organs. While human data are limited, some patients have reported changes in reproductive function. If you are of reproductive age and considering future parenthood, discuss fertility preservation options (such as sperm banking or egg freezing) with your healthcare team before starting treatment. Both male and female patients should use effective contraception during treatment and for at least 2 weeks after the last dose. If you become pregnant during treatment, inform your doctor immediately, as nilotinib may harm the unborn baby.
There is no specific contraindication against moderate alcohol consumption with nilotinib. However, caution is advised for several reasons: alcohol can affect liver function, and nilotinib is metabolized by the liver and can itself cause hepatotoxicity; alcohol may interact with the fasting requirements around dosing; and both alcohol and nilotinib can cause nausea and gastrointestinal symptoms. It is best to discuss your alcohol consumption with your doctor. If permitted, moderate consumption is advisable, and alcohol should not be consumed close to dosing times.
References & Sources
This article is based on the following peer-reviewed sources and international medical guidelines:
- European Medicines Agency (EMA). Nilotinib — Summary of Product Characteristics. Last updated 2025. Available from: www.ema.europa.eu
- Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044-1054. doi:10.1038/leu.2016.5
- Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-984. doi:10.1038/s41375-020-0776-2
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Version 1.2025. Available from: www.nccn.org
- Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. Journal of Clinical Oncology. 2016;34(20):2333-2340.
- Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129(7):846-854. doi:10.1182/blood-2016-09-742205
- World Health Organization (WHO). Model List of Essential Medicines. 23rd edition. Geneva: WHO; 2023.
- European Society for Medical Oncology (ESMO). Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines. Annals of Oncology. 2024.
- Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. American Journal of Hematology. 2011;86(7):533-539.
- British National Formulary (BNF). Nilotinib. National Institute for Health and Care Excellence (NICE). Updated 2025. Available from: bnf.nice.org.uk
Editorial Team
This article was written and reviewed by our medical editorial team, consisting of licensed physicians with specialist qualifications in oncology, hematology, and clinical pharmacology.
Medical Content
iMedic Medical Editorial Team — Specialists in Oncology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board — Independent expert panel following ELN, NCCN, and ESMO guidelines
Evidence Standard
Level 1A — Based on systematic reviews, randomized controlled trials, and international clinical practice guidelines
Last Review
— Next review scheduled within 6 months
All medical content on iMedic.health is created following the iMedic Editorial Standards, which include rigorous fact-checking, peer review by qualified specialists, and adherence to the GRADE evidence framework. We have no commercial funding, and our editorial content is completely independent from pharmaceutical industry influence.